Abbisko builds combination strategy with China rights to X4's mavorixafor

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies.

The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics Co. Ltd. exclusive

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE